Currently Enrolling Trials
Tecentriq (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1. Avastin (bevacizumab) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
The Tecentriq and Avastin combination is specifically indicated for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Tecentriq and Avastin are supplied as intravenous solutions. Tecentriq should be administered intravenously (IV), 1200 mg on day 1 of each 21-day cycle, and Avastin should be administered IV, 15 mg/kg on day 1 of each 21-day cycle.
The FDA approval of the combination was based on the IMbrave150 global Phase III, multicenter, open-label study of 501 patients with unresectable or metastatic HCC who had not received prior systemic therapy. Patients were randomized 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously (IV), 1200 mg on day 1 of each 21-day cycle, and Avastin was administered IV, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib was administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle. People received the combination or the control arm treatment until disease progression or unacceptable toxicity. The two primary endpoints were OS and independent review facility (IRF)-assessed PFS per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Data demonstrated that Tecentriq in combination with Avastin reduced the risk of death (overall survival; OS) by 42% and reduced the risk of disease worsening or death (progression-free survival; PFS) by 41% compared with sorafenib.
Adverse effects associated with the use of the Avastin/Tecentriq combination may include, but are not limited to, the following:
- bleeding in the gastrointestinal tract
Mechanism of Action
Tecentriq (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Avastin (bevacizumab) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer.